Outlook Therapeutics, Inc. announced a private placement of 714,286 shares at a price of $7 per share for the gross proceeds of $5,000,002 and accompanying warrant to purchase one and a half shares of common stock on April 15, 2024. The warrants have an exercise price of $7.70 per share of common stock and will expire on April 15, 2029. The transaction included participation from returning investor,
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.2 USD | -3.10% | +1.84% | -8.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.63% | 17Cr | |
+38.36% | 5.27TCr | |
+38.76% | 3.9TCr | |
-8.63% | 3.85TCr | |
+25.46% | 3.04TCr | |
-11.17% | 2.64TCr | |
+11.44% | 2.61TCr | |
+45.09% | 1.42TCr | |
+32.93% | 1.26TCr | |
-5.30% | 1.15TCr |
- Stock Market
- Equities
- OTLK Stock
- News Outlook Therapeutics, Inc.
- Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC